that the risk of developing a new cancer is very small. 
Risk of Cytovene Therapy: 
Cytovene has been used extensively in humans to treat a number of 
infections including viral infections of the eye. We will be following 
the recommended dose for therapy that has been used to treat viral 
infections of the eye. The most commonly observed complication in 
people receiving Cytovene has been the development of decreased white 
blood cell and platelet counts. This could result in an increased risk 
of infection and bleeding. We will monitor these counts every other day 
(during Cytovene treatment) and the drug will be discontinued if the 
white blood count or platelet count drops significantly. 
Discontinuation of the drug results in normalization of the white blood 
cell and platelet numbers. Cytovene may cause permanent or temporary 
infertility and may be associated with birth defects. Therefore, women 
of childbearing age should use effective contraception during Cytovene 
therapy and men should use contraception during and for at least 90 days 
following Cytovene therapy. Pregnant women are not eligible for this 
protocol. Cytovene can cause cancer in animals. There is no 
information available to estimate the risk of this in humans. 
Additional Risk: 
This procedure is relatively new and it is possible that despite 
our extensive efforts other unforeseen problems may occur including the 
possibility of unknown and possible disabling effects or death. 
A TENTATIVE AGREEMENT TO AN AUTOPSY 
In case of death during or after your participation in this 
research study, we ask you for a tentative agreement to an autopsy. 
This will provide us with an opportunity to learn more about the effect 
of our treatment of the brain tumor. 
ALTERNATIVE TREATMENTS 
Your child has been offered the opportunity to participate in this 
study after your child's tumor recurred despite appropriate standard 
therapies for your child's disease. There are no other standard 
treatments that were shown to have significant effects in patients with 
your child's disease. A variety of experimental studies for the 
treatment of brain tumors are conducted in medical centers around the 
world, but the benefit of their approaches is as yet unknown. In 
addition, there is always the possibility for your child to decline any 
further treatment for his/her disease. 
OTHER PERTINENT INFORMATION 
1. When results of this study are reported at scientific and medical 
meetings or in journals, no patient will be specifically 
identified. Your child's medical records at Childrens Hospital Los 
Angeles will be maintained in accordance with legal requirements 
and will be made available only as required by approved members of 
the Food and Drug administration, National Cancer institute and 
Recombinant DNA Research, Volume 18 
[81] 
